{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:02:08Z","timestamp":1781251328741,"version":"3.54.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hold\u2019em for Life Fellowship Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Age is a prognostic factor in thyroid cancer. However, little is known about benefits and risks of systemic therapy in older adults with advanced thyroid cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>We performed a retrospective review of patients \u2265 65\u2009years of age with advanced thyroid cancer referred to medical oncology at our institution for consideration of systemic therapy between 2010 and 2025 (n\u2009=\u2009114). Clinicopathologic, treatment, adverse event, and outcomes data were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>65\/114 patients received first-line systemic therapy. Median overall survival (OS) was 4.04\u2009years (95% CI, 3.09-not estimable) in the whole cohort and 3.91\u2009years (95% CI, 2.84-not estimable) in the treated cohort. First-line time-to-treatment discontinuation (TTD) in the treated cohort was 1.59\u2009years (95% CI, 0.75-4.45). Age, male sex, and anaplastic histology predicted shorter OS in the whole cohort. Age, male sex, increasing Charlson comorbidity index, and BRAF and\/or TERT mutation predicted worse OS and\/or TTD amongst treated patients. For patients receiving lenvatinib (n\u2009=\u200937), adverse events led to significant proportions of patients requiring dose reductions (65%), treatment breaks (78%), emergency department (ED) visits (16%), and drug discontinuation (14%). Adverse events led to treatment breaks (56%), ED visits (67%), and drug discontinuation (22%) in patients receiving dabrafenib + trametinib (n\u2009=\u20099). Female sex, geriatric oncology referral, polypharmacy, and BRAF mutation predicted higher number of ED visits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although survival outcomes were comparable to those described in younger adults, adverse events were common and impactful in older adults.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag200","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:43:54Z","timestamp":1778845434000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes in older adults with advanced thyroid cancer"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4066-7489","authenticated-orcid":false,"given":"Helena J","family":"Janse van Rensburg","sequence":"first","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto , Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Xiao","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto , Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Lajkosz","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto , Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijithan","family":"Sugumar","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto , Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabbir M H","family":"Alibhai","sequence":"additional","affiliation":[{"name":"Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, University of Toronto , Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2014Head and Neck Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto , Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruz","family":"Mesci","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto , Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly C","family":"Barron","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto , Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1407-0715","authenticated-orcid":false,"given":"Lucy X","family":"Ma","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto , Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"2026061203440111600_oyag200-B1","doi-asserted-by":"publisher","first-page":"e000020","DOI":"10.1136\/esmoopen-2015-000020","article-title":"Challenge of cancer in the elderly","volume":"1","author":"Marosi","year":"2016","journal-title":"ESMO Open"},{"key":"2026061203440111600_oyag200-B2","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1210\/jc.2015-3100","article-title":"The influence of patient age on thyroid nodule formation, multinodularity, and thyroid cancer risk","volume":"100","author":"Kwong","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061203440111600_oyag200-B3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.mcna.2012.01.013","article-title":"Approach to and treatment of thyroid disorders in the elderly","volume":"96","author":"Papaleontiou","year":"2012","journal-title":"Med Clin North Am"},{"key":"2026061203440111600_oyag200-B4","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1200\/JCO.2017.74.5497","article-title":"Patient age\u2013associated mortality risk is differentiated by BRAF V600E status in papillary thyroid cancer","volume":"36","author":"Shen","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026061203440111600_oyag200-B5","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1530\/ERC-15-0396","article-title":"TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population","volume":"22","author":"Qasem","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"2026061203440111600_oyag200-B6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2026061203440111600_oyag200-B7","first-page":"1587","article-title":"Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer","volume":"47","author":"Tuttle","year":"2006","journal-title":"J Nucl Med"},{"key":"2026061203440111600_oyag200-B8","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/RLU.0000000000002078","article-title":"Impact of patient age and histological type on radioactive iodine avidity of recurrent lesions of differentiated thyroid carcinoma","volume":"43","author":"Nakanishi","year":"2018","journal-title":"Clin Nucl Med"},{"key":"2026061203440111600_oyag200-B9","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ejso.2018.07.055","article-title":"Thyroidectomy for thyroid cancer in the elderly: a meta-analysis","volume":"45","author":"Joseph","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"2026061203440111600_oyag200-B10","doi-asserted-by":"publisher","first-page":"e389708","DOI":"10.1200\/EDBK_389708","article-title":"Management of advanced thyroid cancer: Overview, advances, and opportunities","volume":"43","author":"Agosto Salgado","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026061203440111600_oyag200-B11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s44276-025-00153-2","article-title":"Real-world treatment outcomes and clinicopathologic and molecular determinants of response to first-line lenvatinib in patients with advanced follicular cell-derived thyroid cancer","volume":"3","author":"Ruicci","year":"2025","journal-title":"BJC Rep"},{"key":"2026061203440111600_oyag200-B12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13073-016-0364-2","article-title":"Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the princess margaret IMPACT\/COMPACT trial","volume":"8","author":"Stockley","year":"2016","journal-title":"Genome Med"},{"key":"2026061203440111600_oyag200-B13","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.3747\/co.26.5235","article-title":"OCTANE (Ontario-wide cancer targeted nucleic acid evaluation): a platform for intraprovincial, national, and international clinical data-sharing","volume":"26","author":"Malone","year":"2019","journal-title":"Curr Oncol"},{"key":"2026061203440111600_oyag200-B14","volume-title":"R: A Language and Environment for Statistical Com- Puting","author":"RDevelopment Core Team","year":"2010","edition":"4.4.1 ed"},{"key":"2026061203440111600_oyag200-B15","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"key":"2026061203440111600_oyag200-B16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in Radioiodine-Refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"2026061203440111600_oyag200-B17","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1200\/JCO.2016.71.6472","article-title":"Effect of age on the efficacy and safety of lenvatinib in Radioiodine-Refractory differentiated thyroid cancer in the phase III SELECT trial","volume":"35","author":"Brose","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026061203440111600_oyag200-B18","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1089\/thy.2022.0115","article-title":"Dabrafenib versus dabrafenib + trametinib in BRAF-Mutated radioactive iodine refractory differentiated thyroid cancer: Results of a randomized, phase 2, Open-Label multicenter trial","volume":"32","author":"Busaidy","year":"2022","journal-title":"Thyroid"},{"key":"2026061203440111600_oyag200-B19","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1186\/s12877-022-03430-8","article-title":"Development and validation of a nomogram to predict cancer-specific survival in elderly patients with papillary thyroid carcinoma: a population-based study","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Geriatr"},{"key":"2026061203440111600_oyag200-B20","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1210\/jc.2005-0987","article-title":"BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer","volume":"90","author":"Xing","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061203440111600_oyag200-B21","doi-asserted-by":"publisher","first-page":"11435","DOI":"10.1038\/s41598-019-47898-8","article-title":"The relationship of comorbidities to mortality and cause of death in patients with differentiated thyroid carcinoma","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"key":"2026061203440111600_oyag200-B22","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1530\/ERC-15-0533","article-title":"TERT promoter mutations in thyroid cancer","volume":"23","author":"Liu","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"2026061203440111600_oyag200-B23","doi-asserted-by":"publisher","first-page":"vii36","DOI":"10.1093\/annonc\/mdt266","article-title":"Polypharmacy and the management of the older cancer patient","volume":"24 Suppl 7","author":"Balducci","year":"2013","journal-title":"Ann Oncol"},{"key":"2026061203440111600_oyag200-B24","doi-asserted-by":"publisher","first-page":"102303","DOI":"10.1016\/j.jgo.2025.102303","article-title":"Oncologist perspectives on the acceptability, appropriateness, and feasibility of the cancer and aging research group (CARG) chemotherapy toxicity prediction tool for older adults","volume":"16","author":"Johnson","year":"2025","journal-title":"J Geriatr Oncol"},{"key":"2026061203440111600_oyag200-B25","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.23.00933","article-title":"Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update","volume":"41","author":"Dale","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026061203440111600_oyag200-B26","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1111\/jgs.19395","article-title":"Individualized net benefit of intensive blood pressure lowering among Community-Dwelling older adults in SPRINT","volume":"73","author":"Jamshidian","year":"2025","journal-title":"J Am Geriatr Soc"},{"key":"2026061203440111600_oyag200-B27","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.3390\/curroncol28050304","article-title":"Management of pyrexia associated with the combination of dabrafenib and trametinib: Canadian consensus statements","volume":"28","author":"Thawer","year":"2021","journal-title":"Curr Oncol"},{"key":"2026061203440111600_oyag200-B28","doi-asserted-by":"publisher","first-page":"e68066","DOI":"10.7759\/cureus.68066","article-title":"Exploring gender disparities in emergency department utilization: a comprehensive comparative analysis of the frequency of female versus male emergency department visits","volume":"16","author":"Aalam","year":"2024","journal-title":"Cureus"},{"key":"2026061203440111600_oyag200-B29","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s11606-009-1073-y","article-title":"Index to predict 5-Year mortality of Community-Dwelling adults aged 65 and older using data from the national health interview survey","volume":"24","author":"Schonberg","year":"2009","journal-title":"J Gen Intern Med"},{"key":"2026061203440111600_oyag200-B30","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026061203440111600_oyag200-B31","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1503\/cmaj.050051","article-title":"A global clinical measure of fitness and frailty in elderly people","volume":"173","author":"Rockwood","year":"2005","journal-title":"CMAJ"},{"key":"2026061203440111600_oyag200-B32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2407-13-6","article-title":"Differences in the symptom experience of older versus younger oncology outpatients: a cross-sectional study","volume":"13","author":"Cataldo","year":"2013","journal-title":"BMC Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag200\/68345909\/oyag200.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag200\/68345909\/oyag200.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag200\/68345909\/oyag200.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:44:07Z","timestamp":1781250247000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag200\/8688181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag200","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,5,20]]},"article-number":"oyag200"}}